<DOC>
	<DOCNO>NCT00301093</DOCNO>
	<brief_summary>RATIONALE : Vaccines make gene-modified cancer cell may help body build effective immune response kill cancer cell . Imatinib mesylate may stop growth cancer cell block enzymes need cell growth . Giving vaccine therapy together imatinib mesylate may effective treatment chronic myelogenous leukemia . PURPOSE : This phase I trial study side effect best dose vaccine therapy give together imatinib mesylate treat patient chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Vaccine Therapy Imatinib Mesylate Treating Patients With Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose GM-K562 cell vaccine administer imatinib mesylate patient persistent chronic phase chronic myelogenous leukemia first hematologic response . - Determine safety toxic effect GM-K562 cell vaccination patient . Secondary - Determine disease response serial BCR-ABL quantitative polymerase chain reaction measurement patient treat regimen . - Determine development tumor immunity patient treated regimen . OUTLINE : This dose-escalation study GM-K562 . Patients continue receive oral imatinib mesylate stable dose study entry . Patients receive GM-K562 subcutaneously day 1 , 8 , 15 , 29 , 43 , 57 , 85 , 113 , 141 absence disease progression unacceptable toxicity . Cohorts 10 patient receive escalate dos GM-K562 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 10 patient experience dose-limiting toxicity . After completion study treatment , patient follow periodically 20 year . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia Chronic phase disease Philadelphia chromosome positive disease Disease first complete hematologic response , define follow : Complete normalization peripheral blood count WBC &lt; 10,000/mm^3 Platelet count &lt; 450,000/mm^3 No immature cell ( e.g. , myelocyte , metamyelocytes , blast ) peripheral blood Persistent molecular evidence disease Detectable BCRABL transcript quantitative polymerase chain reaction Less 2 log reduction peripheral blood bone marrow BCRABL transcript level compare standardized baseline Must receive imatinib mesylate &gt; 1 year last 3 month stable dose ≥ 300 mg/day PATIENT CHARACTERISTICS : Not pregnant nursing Fertile patient must use effective contraception Negative pregnancy test No know HIV ALT AST ≤ 3 time upper limit normal Oxygen saturation ≥ 93 % room air No history recent acute myocardial infarction No history unstable angina No pulmonary decomposition require hospitalization within past 3 month No concurrent and/or uncontrolled psychiatric medical condition would preclude study compliance PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior allogeneic stem cell transplantation At least 2 month since prior experimental therapy At least 6 month since prior participation another vaccine study No concurrent systemic immunosuppressive medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
</DOC>